TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00564317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDNET
Description: Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDNET
Description: Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDNET
Description: Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation/Relaxation
Description: a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation/Relaxation
Description: a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation/Relaxation
Description: a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
Study: NCT04157036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Subject will take 40mg Methylprednisolone 45 minutes prior to anesthetic delivery
Study: NCT03539029

Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgical fracture fixation
Study: NCT01977001

Intervention type: DEVICE
Intervention: MigraineBoxTM
Study: NCT03329313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lowering sodium concentration dialysate
Description: Concentration of sodium in dialysate at 140 mmol/l

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Highing sodium concentration dialysate
Description: Concentration of sodium in dialysate at 145 mmol/l
Study: NCT03171558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Pull Up
Description: Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Flap Surgery
Description: Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
Study: NCT04842396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental:Motorized cycle ergometer
Description: Cycling training on the MOTOmed Muvi for 20 minutes 3 days per week for 6 weeks. Moreover, control of adverse events throughout the trial was measured through the assessment and monitoring of vital signs before, during (within the first 10 minutes), and after the intervention sessions. Vital signs \[heart rate (per minute), systolic and diastolic blood pressure (in millimeters of mercury, mm Hg), and oxygen saturation (in percentage)\] were monitored by a nurse and a medical doctor using mobile finger pulse oximeters.
Study: NCT02947607

Intervention type: PROCEDURE
Intervention: Colon biopsies

Intervention type: PROCEDURE
Intervention: Colon biopsies

Intervention type: PROCEDURE
Intervention: Colon biopsies
Study: NCT02488382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonquek
Description: Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
Study: NCT02654795

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: computed tomography
Description: CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
Study: NCT00910806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207; nevirapine
Study: NCT00671996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mangafodipir
Description: Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment (0.9% NaCl)
Description: Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
Study: NCT04374500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin infusion plus vasodilators in healthy men
Description: This applies only to protocol 2 with two arms (leptin or saline) where four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) were infused concomitantly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin infusion in healthy men
Description: This applies only to protocol 1 when only leptin was given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasodilators in CAD patients
Description: This applies only to protocol 3
Study: NCT02053194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Description: 1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
Study: NCT04293809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: bupivacaine liposome injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: bupivacaine liposome injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 1.3%, 13.3 mg/mL
Study: NCT03539029

Intervention type: PROCEDURE
Intervention: Conservative treatment
Description: immobilisation with plaster cast
Study: NCT04163315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dMRI, fMRI and electrocorticography
Description: Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
Study: NCT01914965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
Study: NCT00275015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study: NCT03534011

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resuscitative Balloon Occlusion of the Aorta
Description: If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA catheter
Description: Catheter with a Resuscitative Balloon for Occlusion of the Aorta
Study: NCT02514226

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: supragingival treatment
Description: In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal treatment
Description: All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periodontal treatment and photodynamic therapy
Description: In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets \> 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dental hygiene orientation
Description: Plaque Control through the use of toothbrush and floss

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dental hygiene orientation
Description: Plaque Control through the use of toothbrush and floss

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dental hygiene orientation
Description: Plaque Control through the use of toothbrush and floss
Study: NCT04860856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Description: The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 20ml of normal saline
Study: NCT01547221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clotrimazole
Description: single application of 1%clotrimazole ear drop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Boric acid
Description: 3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
Study: NCT00826228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: teriparatide 20ug daily sc for 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight-bearing
Description: device assisted walking
Study: NCT01782729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
Study: NCT00113269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basiliximab
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabbit anti-thymocyte globulin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids
Description: IV and/or oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids
Description: IV and/or oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroids
Description: IV and/or oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroids
Description: IV and/or oral
Study: NCT04596176

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Program Supportive Housing Services
Description: The existing statewide SH model that included routine access to housing (voucher) and case management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Supportive Housing Services
Description: an intensive treatment SH model with a higher dosage of case management, family teaming, and access to a vocational specialist
Study: NCT00514800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention - a validated home BP monitor and support from the specialist nurse

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - usual care (BP monitoring by their practice)
Description: Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings.
Study: NCT03767972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy-based device
Description: Patients will receive one treatment for rejuvenation using one or multiple energy-based devices based on investigator discretion.
Study: NCT04290611

Intervention type: DRUG
Intervention: Enzalutamide
Description: Enzalutamide for the treatment of prostate cancer or other solid tumors
Study: NCT02071680

Intervention type: OTHER
Group type: OTHER
Intervention: Iodine-123 Meta-iodobenzylguanidine
Description: A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point.
Study: NCT02851849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGD-6972-5 mg
Description: 5 mg LGD-6972 QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGD-6972-10 mg
Description: 10 mg LGD-6972 QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGD-6972-15 mg
Description: 15 mg LGD-6972 QD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD
Study: NCT03840356

Intervention type: OTHER
Intervention: Postoperative
Description: No intervention is planned in the study. This study is simply evaluating the consistency with which patients report their pain levels to different members of the medical team.
Study: NCT00853372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
Study: NCT03631303

Intervention type: DEVICE
Intervention: Cardiac stimulation through the device leads
Description: During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.

Intervention type: DEVICE
Intervention: Cardiac stimulation through the device leads
Description: During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.

Intervention type: DEVICE
Intervention: Cardiac stimulation through the device leads
Description: During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
Study: NCT01130311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
Study: NCT03320395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Small bowel RFA treatment
Description: The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.~The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.~12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.~There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites.
Study: NCT00275015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02982148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methylene blue intradermal injection
Description: Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue subcutaneous injection
Description: Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
Study: NCT02829502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byetta
Description: Single dose of subcutaneous injection of 5 μg exenatide (Byetta).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normosaline
Description: Single dose of subcutaneous injection of 20 μL normosaline (placebo).
Study: NCT01575002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
Study: NCT00846690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine
Description: 20% benzocaine., topical placement onto site, minimal amount, for 1 minute

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC alternate gel
Description: use 1 pump, place topically onto site, leave for 1-3 minutes